|
Mar 19
|
Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Q4 2023 Eyenovia Inc Earnings Call
|
|
Mar 18
|
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 18
|
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
|
Mar 13
|
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
|
|
Mar 11
|
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
|
|
Mar 5
|
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation
|
|
Mar 5
|
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
|
|
Mar 4
|
UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says
|
|
Jan 16
|
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
|
|
Aug 9
|
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
|
|
Aug 7
|
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
|
|
Aug 3
|
Eyenovia Announces First Commercial Sale of Mydcombi™
|
|
Apr 24
|
Eyenovia Announces Poster Presentation at ARVO 2023
|